Related Experiment Video
Updated: Jul 21, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Portopulmonary Hypertension: An Updated Review.
Erick A Jasso-Baltazar1, Gonzalo A Peña-Arellano2, Jonathan Aguirre-Valadez3
1Department of Gastroenterology and Liver Transplant Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Portopulmonary hypertension (PoPH) is a serious condition linked to liver disease. Early diagnosis and treatment, including liver transplantation, are crucial for improving outcomes in affected patients.
Area of Science:
- Cardiology
- Hepatology
- Pulmonology
Background:
- Portal hypertension significantly impacts pulmonary vasculature.
- Portopulmonary hypertension (PoPH) is a severe pulmonary vascular disease secondary to portal hypertension.
- PoPH is the fourth most common subtype of pulmonary arterial hypertension, affecting both cirrhotic and non-cirrhotic patients.
Purpose of the Study:
- To review the epidemiology, pathophysiology, diagnosis, and treatment of PoPH.
- To detail current management strategies, including orthotopic liver transplantation (OLT).
- To present a diagnostic algorithm for selecting OLT candidates with PoPH.
Main Methods:
- Review of existing literature on PoPH.
- Description of diagnostic procedures including echocardiography and right heart catheterization.
- Analysis of treatment outcomes and OLT candidacy criteria.
Main Results:
- PoPH is a critical complication of portal hypertension with poor prognosis if untreated.
- Transthoracic echocardiogram and right heart catheterization are key diagnostic tools.
- Management involves pulmonary arterial hypertension therapies and consideration for OLT.
Conclusions:
- Accurate diagnosis and timely intervention are vital for PoPH management.
- Orthotopic liver transplantation offers a potential treatment pathway for select PoPH patients.
- A structured diagnostic approach aids in patient selection for OLT.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

